Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR NASDAQ:BHST NASDAQ:FLNA NASDAQ:MYNZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.59$0.58$0.40▼$7.29$58.10M0.522.17 million shs1.48 million shsBHSTBioHarvest Sciences$2.87$3.58$2.74▼$12.80$56.30M0.8723,622 shs1,039 shsFLNACassava Sciences$1.23$1.33$1.15▼$4.98$59.42M-0.73325,459 shs637,068 shsMYNZMainz Biomed$1.45-5.8%$1.79$0.55▼$4.43$13.14M0.31371,589 shs1.22 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma0.00%+12.32%+15.50%-30.04%-88.78%BHSTBioHarvest Sciences0.00%+2.32%-11.69%-32.94%-57.92%FLNACassava Sciences0.00%+2.50%-12.14%-28.90%-38.81%MYNZMainz Biomed0.00%-11.04%-41.06%+216.52%+1.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.59$0.58$0.40▼$7.29$58.10M0.522.17 million shs1.48 million shsBHSTBioHarvest Sciences$2.87$3.58$2.74▼$12.80$56.30M0.8723,622 shs1,039 shsFLNACassava Sciences$1.23$1.33$1.15▼$4.98$59.42M-0.73325,459 shs637,068 shsMYNZMainz Biomed$1.45-5.8%$1.79$0.55▼$4.43$13.14M0.31371,589 shs1.22 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma0.00%+12.32%+15.50%-30.04%-88.78%BHSTBioHarvest Sciences0.00%+2.32%-11.69%-32.94%-57.92%FLNACassava Sciences0.00%+2.50%-12.14%-28.90%-38.81%MYNZMainz Biomed0.00%-11.04%-41.06%+216.52%+1.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 2.25Hold$17.002,769.20% UpsideBHSTBioHarvest Sciences 2.00Hold$10.00248.43% UpsideFLNACassava Sciences 2.00Hold$5.00306.50% UpsideMYNZMainz Biomed 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest MYNZ, ATYR, FLNA, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2026ATYRaTyr Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/18/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026FLNACassava Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/22/2026ATYRaTyr Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/20/2026ATYRaTyr Pharma Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/22/2026FLNACassava Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr Pharma$190K305.76N/AN/A$0.69 per share0.86BHSTBioHarvest Sciences$34.51M1.63N/AN/A$1.30 per share2.21FLNACassava SciencesN/AN/AN/AN/A$1.54 per shareN/AMYNZMainz Biomed$659.94K19.91N/AN/A$2.61 per share0.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$74.12M-$0.73N/AN/AN/AN/A-100.14%-73.55%8/6/2026 (Estimated)BHSTBioHarvest Sciences-$11.14M-$0.59N/AN/AN/A-32.54%-76.03%-25.30%8/10/2026 (Estimated)FLNACassava Sciences-$90.97M-$1.61N/AN/AN/AN/A-53.90%-34.20%N/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ALatest MYNZ, ATYR, FLNA, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ATYRaTyr Pharma-$0.16-$0.11+$0.05-$0.11N/AN/A5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13-$0.11+$0.02-$0.11$8.50 million$8.51 million5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr PharmaN/A5.785.78BHSTBioHarvest Sciences0.032.962.44FLNACassava SciencesN/A2.192.19MYNZMainz Biomed0.440.520.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%BHSTBioHarvest SciencesN/AFLNACassava Sciences38.05%MYNZMainz BiomedN/AInsider OwnershipCompanyInsider OwnershipATYRaTyr Pharma5.75%BHSTBioHarvest SciencesN/AFLNACassava Sciences4.60%MYNZMainz Biomed18.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5398.05 million92.41 millionOptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/AFLNACassava Sciences2048.31 million46.09 millionOptionableMYNZMainz Biomed309.06 million7.41 millionNot OptionableMYNZ, ATYR, FLNA, and BHST HeadlinesRecent News About These CompaniesMainz BioMed NV: Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors / Name change to Quantum Cyber (QUCY)March 12, 2026 | finanznachrichten.deStrategische Neuausrichtung: Mainz Biomed firmiert in Quantum Cyber um und ernennt neuen ChairmanMarch 11, 2026 | de.investing.comMainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsMarch 11, 2026 | globenewswire.comMainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood SamplesFebruary 24, 2026 | markets.businessinsider.comMainz Biomed sichert sich 6 Millionen US-Dollar und richtet Fokus auf BauchspeicheldrüsenkrebsFebruary 17, 2026 | de.investing.comMainz Biomed secures $6 million private placement, shifts focus to US pancreatic cancer programFebruary 17, 2026 | msn.comMainz Biomed Announces 6.0 USD Million Private Placement and Strategic UpdateFebruary 17, 2026 | finance.yahoo.comMainz Biomed nimmt 2,15 Mio. US-Dollar über At-the-Market-Platzierung ein/nFebruary 10, 2026 | de.investing.comMainz Biomed Aktie: Neue Studiendaten vorausFebruary 7, 2026 | stock-world.deSMainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual MeetingJanuary 14, 2026 | globenewswire.comMainz Biomed expects to complete eAArly DETECT 2 study in 2026January 6, 2026 | msn.comMainz Biomed Provides Review of 2025 HighlightsJanuary 5, 2026 | markets.businessinsider.comMainz Biomed Initiates eAArly DETECT 2 Clinical Study to Evaluate Next Generation Colorectal Cancer Test and Advances Pancreatic Cancer Screening ProgramJanuary 5, 2026 | quiverquant.comQMainz Biomed files $150M mixed securities shelfDecember 5, 2025 | msn.comMainz Biomed announces ColoAlert added to portfolio of DoctorBoxDecember 2, 2025 | msn.comDoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its PortfolioDecember 2, 2025 | markets.businessinsider.comMainz BioMed NV: Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | finanznachrichten.deMainz Biomed, OncoVanguard8 agree to bring ColoAlert to South AmericaNovember 18, 2025 | msn.comMainz Biomed Signs Memorandum of Understanding with OncoVanguard8 to Launch ColoAlert® Colorectal Cancer Screening in South AmericaNovember 18, 2025 | quiverquant.comQMainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South AmericaNovember 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYNZ, ATYR, FLNA, and BHST Company DescriptionsaTyr Pharma NASDAQ:ATYR$0.59 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.59 +0.00 (+0.08%) As of 07/2/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.BioHarvest Sciences NASDAQ:BHST$2.87 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.88 +0.01 (+0.38%) As of 07/2/2026 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Cassava Sciences NASDAQ:FLNA$1.23 0.00 (0.00%) As of 07/2/2026 04:00 PM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.Mainz Biomed NASDAQ:MYNZ$1.45 -0.09 (-5.84%) As of 07/2/2026Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
